Electra Therapeutics Targets Up to $978 Million Valuation in U.S. IPO
Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according to a filing on Monday, adding to a broader recovery in biotech listings this...